🇺🇸 FDA
Patent

US 11191780

Extracellular matrix compositions for the treatment of cancer or immunological diseases

granted A61KA61K35/12A61K35/33

Quick answer

US patent 11191780 (Extracellular matrix compositions for the treatment of cancer or immunological diseases) held by Adaptive Biologix, Inc. expires Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time). Status: granted.

Key facts

Applicant
Adaptive Biologix, Inc.
Grant date
Tue Dec 07 2021 00:00:00 GMT+0000 (Coordinated Universal Time)
Expiration
Mon Dec 02 2041 00:00:00 GMT+0000 (Coordinated Universal Time)
Claims
8
CPC classes
A61K, A61K35/12, A61K35/33, A61K38/014, A61K45/06